GENERAL QUESTIONS. 1.0 Has the Authorized User received the necessary internal approvals for this request? [Authorized Users are advised that it is their responsibility to secure the necessary internal approvals. A Mini-Bid request for NYS Executive Agencies that has not received approval of the applicable business case and received a B-1184 number may be rejected by OGS Fleet Management]
GENERAL QUESTIONS. For questions of a general nature relating to interpretation of the collective agreement, Dansk Erhverv Arbejdsgiver and HK can request that a meeting be held immediately at Dansk Erhverv Arbejdsgiver’s offices so the matter can be discussed. Such a main committee meeting must normally be held no later than four weeks after the request is made. Disputes concerning the rules in this section, including compliance with the deadlines, must be brought before the main committee.
GENERAL QUESTIONS. Answer each question by checking the Yes or No selection. For every question marked “Yes” you must provide an explanation in the space provided below. Questions Yes No
GENERAL QUESTIONS. Please answer questions a. and b. in relation to this business or any previous business in which the proprietor, partners or directors have traded, in this or any other name:
GENERAL QUESTIONS. 2.1. What is DIH-World? DIH-World is a European project, precisely an Innovation Action, supported by the European Commission through the ICT Innovation for Manufacturing SMEs (I4MS) initiative. DIH-World aims to accelerate the uptake of advanced digital technologies by European manufacturing SMEs in all sectors by supporting them in building sustainable competitive advantages and reaching global markets. Through two open calls, the project will support a total of 45 innovative experiments. The open call for experiments 1 will support up to 35 innovative experiments.
GENERAL QUESTIONS. Dansk Erhverv Arbejdsgiver and HK may, in matters of a general nature con- cerning the understanding of the collective agreement, request that a meeting be held at Dansk Erhverv Arbejdsgiver's office to discuss the matter. Such a meeting must normally be held no later than 4 weeks after the request for such a meeting. Disputes regarding the rules in this section, including compliance with the time limits, must be brought before the Executive Committee for processing.
GENERAL QUESTIONS. 1. I am a Vaccines for Children (VFC) Provider and submit a Provider Agreement each year. Do I still need to fill out a COVID-19 Vaccination Program Provider Agreement? Yes. The VFC and COVID-19 Provider Agreements are separate agreements. Any provider receiving and administering COVID-19 vaccine will need to sign a COVID-19 Provider Agreement.
GENERAL QUESTIONS. 1. Why are we ending the Space Shuttle Program? In 2004, President Xxxxxx X. Xxxx announced a new exploration initiative, the Vision for Space Exploration. As part of this initiative, NASA will continue to use the space shuttle fleet to fulfill its obligation to complete assembly of the International Space Station and then retire the fleet by the end of 2011. Congress expressly endorsed the President’s exploration initiative.
GENERAL QUESTIONS. The Authorised Reseller also agrees to respond to any questions Expo may have about Ticket sales, trends, marketing activities and any other relevant issues. Reports and answers to such questions shall be due and delivered within 10 (ten) days of the request having been made by Expo, or within such other period of time as Expo may reasonably direct. The Authorised Reseller warrants the accuracy of the information provided to Expo.
GENERAL QUESTIONS. Q1: Give me a high-level explanation of the kinds of health plan coverage information you are capturing in order to better coordinate benefits between my health plan and Medicare? A1: VDSA partners and CMS exchange databases on a regular basis. The Non-MSP File (Non-Medicare secondary payer file) is used to capture and report drug coverage that is secondary to Medicare (such as benefits for covered retirees and their covered spouses and dependents). We need this specific drug coverage data to help the Part D plans calculate the beneficiaries’ True Out-Of-Pocket costs and to help pharmacies bill in the correct payer order at the pharmacy point of sale.